



13700 Mayfield Place, Suite 2135
Richmond, BC V6V 2E4 Canada
Phone: 604-270-4344
Fax: 604-270-4384
www.neovasc.com

NEOVASC TO PRESENT AT RODMAN AND RENSHAW ANNUAL GLOBAL INVESTMENT CONFERENCE AND UBS GLOBAL HEALTHCARE CONFERENCE

--A Live Webcast of the UBS Presentation will be Available on the Neovasc Website--

September 7, 2011 – Vancouver, BC, Canada – Neovasc Inc. (TSXV: NVC), a specialty vascular device company, today announced that senior management will present at the upcoming 2011 Rodman and Renshaw Annual Global Investment Conference and 2011 UBS Global Life Sciences Conference. Neovasc chief executive officer Alexei Marko will provide an update on recent corporate developments and expected product development milestones. Mr. Marko and Neovasc chief financial officer Christopher Clark will participate in post-presentation breakout sessions at the conferences.

The Neovasc Rodman and Renshaw conference presentation is scheduled for September 13, 2011 at 2:50pm EDT. The conference is being held at the Waldorf Astoria Hotel in New York City.

For more information about the 2011 Rodman and Renshaw Annual Global Investment Conference, visit <http://www.rodmanandrenshaw.com/conferences?id=162>.

The Neovasc UBS Global Life Sciences Conference presentation is scheduled for September 21, 2011 at 2:30pm EDT. The conference is being held at the Grand Hyatt Hotel in New York City.

The audio portion of the company's UBS presentation will be webcast live. It can be accessed at the Investors section of the Neovasc website at www.neovasc.com. An archived version of the webcast will be available on the Neovasc website for 30 days beginning about three hours after the start of the presentation.

About Neovasc Inc.

Neovasc Inc. is a specialty vascular device company that develops, manufactures and markets medical devices for the rapidly growing vascular and surgical marketplace. The company's current products include the Neovasc Reducer™, an innovative product to treat refractory angina, the Tiara™ program developing novel transcatheter technologies for treating mitral valve disease and a line of advanced biological tissue products that are used to enhance surgical outcomes and as key components in a variety of third-party medical products, such as transcatheter heart valves. For more information, visit: www.neovasc.com.

###

Corporate contact:

Neovasc Inc.
Chris Clark
604 249-4138

U.S. media & investor contact:

GendeLLindheim BioCom Partners
Barbara Lindheim or Jennifer Anderson
212 918-4650